Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes
申请人:Attenua, Inc.
公开号:US09580434B2
公开(公告)日:2017-02-28
Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α4β2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle).
本发明涉及化合物、包括该化合物的制药组合物以及其制备和使用方法。该化合物是酰胺化合物,可以由某些杂环羧酸和某些二氮杂双环烷制备而成。该化合物对中枢神经系统(CNS)中的α4β2亚型神经尼古丁受体具有选择性和高亲和力。该化合物和组合物可用于治疗和/或预防各种疾病或疾病,特别是CNS疾病。该化合物可以:(i)改变患者大脑尼古丁胆碱受体的数量,(ii)表现出神经保护作用,以及(iii)在有效剂量下,不会产生明显的不良副作用(例如显著增加血压和心率、对胃肠道产生显著负面影响以及对骨骼肌产生显著影响等副作用)。